
🌍 PulseCath is expanding their global footprint
Exciting news! Another milestone reached. We are proud to announce the achievement of product registration for…
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
> 45 countries approved registrations
> 100 shared cases on LinkedIn; > 200 reported cases
> 35 distributor agreements
> 35 hospitals use iVAC 2L on a regular base; > 7 Centers of Excellence.
> 400 patients world wide treated by iVAC 2L
> 30 publications
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
Clinical programme supported by leading cardiologists